By a News Reporter-Staff News Editor at Gastroenterology Week -- A new study on Inflammatory Bowel Disease is now available. According to news reporting originating in Edmonton, Canada, by NewsRx journalists, research stated, "Vitamin D deficiency is commonly diagnosed among patients with inflammatory bowel disease (IBD). Patients with IBD are at risk of low bone density and increased fractures due to low vitamin D levels, long standing disease, and frequent steroid exposures; as a result, it is well established that vitamin D supplementation in this population is important."
The news reporters obtained a quote from the research from the University of Alberta, "There is increasing support for the role of vitamin D in strengthening the innate immune system by acting as an immunomodulator and reducing inflammation in experimental and human IBD. The active form of vitamin D, 1,25(OH)D3, acts on T cells to promote T helper (Th)2/regulatory T responses over Th1/Th17 responses; suppresses dendritic cell inflammatory activity; induces antibacterial activity; and regulates cytokine production in favor of an anti-inflammatory response. Murine and human IBD studies support a therapeutic role of vitamin D in IBD. Risk factors for vitamin D deficiency in this population include decreased sunlight exposure, disease duration, smoking, and genetics. Vitamin D normalization is associated with reduced risk of relapse, reduced risk of IBD-related surgeries, and improvement in quality of life. Vitamin D is an inexpensive supplement which has been shown to improve IBD outcomes."
According to the news reporters, the research concluded: "However, further research is required to determine optimal serum vitamin D levels which will achieve beneficial immune effects, and stronger evidence is needed to support the role of vitamin D in inducing disease response and remission, as well as maintaining this improvement in patients' disease states."
For more information on this research see: Vitamin D improves inflammatory bowel disease outcomes: Basic science and clinical review. World Journal of Gastroenterology, 2014;20(17):4934-4947. World Journal of Gastroenterology can be contacted at: Baishideng Publishing Group Inc, 8226 Regency Dr, Pleasanton, CA 94588, USA. (Baishideng Publishing Group - www.wjgnet.com/; World Journal of Gastroenterology - www.wjgnet.com/1007-9327/current.htm)
Our news correspondents report that additional information may be obtained by contacting K.M. Reich, University of Alberta, Div Gastroenterol, Edmonton, AB T6G 2X8, Canada. Additional authors for this research include R.N. Fedorak, K. Madsen and K.I. Kroeker (see also Inflammatory Bowel Disease).
Keywords for this news article include: Canada, Alberta, Edmonton, Genetics, Therapeutics, Gastroenteritis, North and Central America, Gastrointestinal Diseases, Inflammatory Bowel Diseases
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC